NXP002 (inhaled tranilast) idiopathic pulmonary fibrosis (IPF) preclinical ongoing

Our lead asset and a potential novel inhaled treatment for IPF

  • Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation.
  • Tranilast has a long history of safe use as an oral drug for allergies but there is evidence (widely published in peer reviewed scientific papers) that supports its potential in fibrosis, including IPF.
  • Overall findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated extra-cellular matrix (ECM) protein  production, a major therapeutic target in IPF, presenting it as a promising and novel anti-fibrotic agent.1
  • NXP002 is differentiated as it is a new form of tranilast and will be formulated for delivery direct to the lungs by inhalation, a new route of administration for this drug.
  • Delivery by the inhalation route is a well-known strategy for treatment of lung diseases to yield greater efficacy and reduce systemic side-effects compared to oral treatment.
  • We have filed two patent applications on new forms of tranilast, one of which is granted and the other is undergoing examination.
  • Our studies have yielded positive data underpinning the potential of NXP002 as an IPF treatment, including potential for use in combination with standard of care therapy and support continuing to develop this asset.
  • Further preclinical studies planned prior to seeking licensing/partnering opportunities.

1Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway in Drug Design, Development and Therapy 2020:14, Kato, M et al